SCM CGH
Alternative Names: Graft versus host disease mesenchymal stem cell therapy - SCM Lifescience; SCM CGHLatest Information Update: 26 Jul 2022
At a glance
- Originator SCM Lifescience
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Graft-versus-host disease
Most Recent Events
- 26 Jul 2022 SCM CGH is still in phase II trials for Graft-versus-host disease in South Korea (KCT0003656)
- 26 Aug 2019 SCM Lifescience has patents and pending applications covering the stem cell technology and its use for various indications, in several countries (SCM Lifescience website, August 2019)
- 23 Aug 2019 Graft versus host disease stem cell therapy - SCM Lifescience receives Orphan Drug status for Graft-versus-host disease in South Korea (SCM Lifescience pipeline, August 2019)